Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss
Company Still Sees Profit Potential Even With US Generic Competitors
A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.
You may also be interested in...
Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.
Promotional efforts will include distinguishing icosapent ethyl from fenofibrates, niacin and omega-3 mixtures, which have failed to demonstrate CV risk reduction in clinical studies. Company execs highlight flexibility provided by the US FDA in expanded labeling and dismiss concerns over absence of CV death risk reduction from indication statement.
John Thero insists company is focused on approval and launch, as interest in European rights grow.